20.11.2026
New daily pill could slow progression of Alzheimer’s
A clinical trial supported by Join Dementia Research has found that a new drug similar to Viagra can slow cognitive decline by almost a third in people with early stage Alzheimer’s disease who are not taking other dementia medications.
Alzheimer’s is the most common type of dementia and causes problems with memory, thinking, language or perception. There is currently no cure.
The Polaris-AD study involved 1,535 participants across 13 countries. This includes UK participants who signed up through Join Dementia Research.
How the drug works
The drug, called AR1001, was developed by South Korean biopharmaceutical company AriBio. It works by relaxing blood vessels, which increases blood flow to the brain. It may also stimulate pathways in brain cells that support learning and memory.
The trial found that the drug slowed cognitive decline by 31% in participants with early Alzheimer’s who were not taking other dementia medications.
Next steps for the trial
Dementia charities and leading researchers have welcomed the findings as an encouraging milestone. However, they stressed that further trials are needed. AR1001 must go through full scientific review and approval before doctors can prescribe it.
Experts also advise that people do not take Viagra to try to manage Alzheimer’s symptoms.
Take part in dementia research
Professor Paresh Malhotra, NIHR Research Delivery Network (RDN) National Specialty Lead for Dementias, said:
“The results of this trial are promising and mark an important step in Alzheimer’s research. They show the value of exploring new ways to slow down the disease, such as improving blood flow to the brain.
“Thank you to everyone who took part in the study, including those who signed up through Join Dementia Research. Progress like this is not possible without its participants.”
Whether you have a dementia diagnosis or not, you can sign up to Join Dementia Research today to find studies that suit you.